Chapter 23: The Breast: Pathology and Disease

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to the Deep Dive.

Today we are, we're shifting gears a bit.

Usually we take a stack of journal articles or some trending topic and just kind of tear it apart.

But today we are back to school, literally.

We are doing a specialized session we're calling the Last Minute Lecture.

Yeah, it's a bit of a departure for us, but honestly a necessary one.

We know a huge chunk of you listening are medical students, pathology residents,

or just healthcare pros who are staring down a board exam or a really brutal rotation.

You don't need the fluff right now.

You need the hard science.

Exactly.

So we are taking one specific chapter, chapter 23, the breast from absolute gold standard, the Bible of pathology.

That is Robbins, Cotran, and Kumar pathologic basis of disease, specifically the 11th edition.

Right.

And our rule for today is simple.

If it's not in Robbins, it doesn't exist for the purposes of this hour.

We are going strictly by the book to give you a reliable study companion.

That is the rule.

So my job today is basically to play the role of the student who has, you know, read the text but maybe didn't quite grasp the why behind everything.

And your job is to translate that incredibly dense academic text into a narrative that actually sticks in the brain.

I will do my best.

Chapter 23 is massive, but it's actually surprisingly logical.

It tells a clear story.

We're going to start with the normal anatomy because honestly, if you don't understand the terminal duct lobular unit, you cannot understand the cancers.

Then we'll move through the developmental anomalies, the inflammatory stuff, those benign lumps that scare everyone, the risk ladder of proliferation, and finally the heavy hitter, which is carcinoma.

And specifically, I want to make sure we drill down into the molecular classification of carcinoma.

The book makes it very clear that just looking at a slide isn't enough anymore.

You have to know the genetics.

Oh, absolutely.

That is the biggest paradigm shift in modern breast pathology.

We don't just say breast cancer anymore.

We ask, is it luminal A?

Is it HER2 positive?

Is it basal -like?

Because the biology completely dictates the targeted treatment.

Okay.

Well, let's not get ahead of ourselves.

Let's start right at the beginning, the landscape.

When I look at figure 23 .1 in the text, I see this schematic of the breast.

To me, it looks like a complex root system or maybe a bunch of grapes.

The grape analogy is the classic one for very good reason.

Imagine the nipple as the starting point of the vine.

You have these major collecting ducts that dive deep into the chest wall.

They branch and branch again, getting smaller and smaller until they finally end in these little clusters of grapes.

Those clusters are the lobules.

And the terminology the book uses here is very specific.

It keeps mentioning the TDLU.

Right, the TDLU.

That stands for terminal duct lobular unit.

It's the combination of the lobule, the grape cluster, and the very final tiny branch of the duct leading right into it.

This is the functional unit of the breast.

This is where the milk is made.

But more importantly for us studying pathology, this is where the vast majority of breast cancers originate.

So if we zoom in on that grape, what are we actually looking at biologically?

It's not just a single layer of cells, is it?

No, and this distinction is probably the single most important concept in the first 10 pages of the chapter.

You have a two cell layer lining all these ducts and lobules.

Okay, lay them out for me.

First, you have the luminal epithelial cells.

These are the inner lining.

If you're looking at a cross section of a duct under the microscope, these are the cells directly touching the lumen, the empty space in the middle.

Their job is functional.

They are the workers that produce the milk.

And the second type of cell, the myoepithelial cells.

These sit right on the outside of the luminal cells sandwiched between those workers and the basement membrane.

Now, myo means muscle.

So these cells are contractile.

During lactation, they physically squeeze the assini to eject the milk into the ducts.

But in a pathology context, they have a completely different job, don't they?

They aren't just there to squeeze milk.

Right.

In pathology, you need to think of the myoepithelial cells as the bounders.

They're the security guard layer.

As long as that layer of myoepithelial cells is intact and continuous around the outside, the lesion is benign, or at worst, it's in situ.

So if I'm a student looking at a slide and I see this big, ugly, scary looking mass of cells inside the duct,

but I can prove with a stain that there's still a rim of myoepithelial cells around it.

Then it is definitively not invasive cancer.

It might be carcinoma in situ.

It might be severe hyperplasia, but it hasn't broken the barrier.

The exact moment those malignant tumor cells breach the myoepithelial layer and eat through the basement membrane, the bouncers are dead, the gate is open, and you have invasive carcinoma.

That's a really helpful visualization.

The bouncers holding the line.

Okay.

Now, the book makes a big point that the breast isn't a static organ.

It changes constantly based on hormones throughout a woman's life.

It's one of the most dynamic tissues in the human body.

It actually cycles every single month.

After ovulation, when estrogen and progesterone levels spike, this actually causes the cells in the lobules to proliferate.

If you've seen you physically swell, there's a bit of edema fluid in the surrounding stroma.

Is that why so many patients feel that kind of lumpiness or tenderness right before their period?

It's a real structural change, not just fluid retention.

Exactly.

It's a physiologic structural change.

The breast is physically getting gentler and larger with more cells.

Then menstruation hits, hormone levels crash, and those newly proliferated cells die off via apoptosis.

The lobules shrink back down.

It's this constant monthly cycle of construction and demolition.

What about pregnancy then?

Because that has to be the most extreme version of this It is.

During pregnancy, the construction phase goes into absolute overdrive and just stays there.

The lobules expand massively to prepare for lactation.

By the time a woman is in her third trimester, if you look at a histology slide of the breast, it's almost entirely lobules.

The connective tissue is compressed so much it's barely visible.

Now, there is a specific clinico -pathologic correlation box in rodents here that links this pregnancy change to breast cancer risk,

and honestly, it seems counterintuitive at first glance.

Yeah, it confuses a lot of people.

The epidemiological data shows that women who give birth at a younger age, specifically before age 20,

have a significantly lower lifetime risk of developing breast cancer compared to women who never have children or who have their first child very late in life.

But why?

Because you'd think all that rapid cellular growth and massive hormone exposure during pregnancy would just throw fuel on the fire for cancer mutations?

It comes down to terminal differentiation.

When the breast goes through the full complete cycle of pregnancy and lactation, the luminal cells finally mature completely.

They become highly specialized milk -producing machines.

Once a cell is fully specialized or terminally differentiated, it becomes much more genomically stable.

It is far less likely to go rogue and acquire the mutations needed for cancer.

So the tissue essentially grows up and settles down.

Exactly.

If you delay that first pregnancy until your late 30s or 40s, those epithelial cells spend decades in a less differentiated, somewhat immature state, constantly cycling up and down every month.

That leaves many, many more windows of opportunity for random genetic mutations to accumulate.

Okay, that makes perfect sense now.

Let's move from normal development to the oops moments of development, the embryology section.

The book talks about this concept of the milk line.

This is a great reminder that humans are mammals.

In many mammals, like dogs or pigs, you have a whole row of nipples.

In human embryos, we all start out with a milk line, which is a bilateral band of thickened epidermis that runs from the axilla of the armpit all the way down the chest and abdomen to the perineum.

But usually, that whole line disappears before birth?

Usually, yes.

It regresses everywhere except for the two specific spots on the pectoral chest wall.

But sometimes, it doesn't completely regress.

And that's when you get polythelia, or supernumerary nipples.

They can pop up anywhere along that original embryonic line.

I feel like I've heard stories of people, or even doctors, mistaking these for common moles.

It happens all the time.

A patient might go to a dermatologist to get a weird mole checked on their abdomen.

And under the microscope, the pathologist sees it's essentially a tiny malformed nipple.

It's completely benign, of course.

But because it is technically real breast tissue, it can technically develop any disease that normal breast tissue can, including breast cancer, right there on the stomach.

Wow.

Okay, there's another developmental anomaly mentioned that seems much more clinically dangerous.

And that's accessory axillary breast tissue.

Right.

This involves the tail of spence.

The normal breast ductal system doesn't just stop at the perfect circular boundary of the breast mound on the chest.

It naturally extends upward and outward deep into the armpit.

Sometimes that extension is very substantial.

And why is that specifically a risk?

Let's imagine a patient with a known BRCA mutation who makes the difficult decision to have a bilateral prophylactic mastectomy to prevent cancer.

The surgeon goes in and removes the main breast mounds.

But if they are incredibly meticulous about digging out that tail of spence deep up in the axilla, they leave functional breast tissue behind.

And that leftover tissue has the same BRCA mutation so it can still get cancer.

There have been tragic cases where a woman thinks her risk is virtually zero because of the preventative surgery, and then develops an invasive breast cancer lump in her armpit five or ten years later.

That is terrifying, but a really crucial anatomical detail for any future surgeons listening.

Now, one last developmental issue.

Nipple inversion.

This is very common.

The nipple simply fails to avert or pop out during development.

If a structural nuisance.

Maybe getting a baby to latch for breastfeeding is a bit harder, but it's absolutely not a disease.

However, Robbins puts a massive flashing warning sign next to this topic.

Huge warning sign.

If a patient has had normal inverted nipples her entire life, and suddenly at age 50 one of them retracts or inverts, that is not developmental, that is mechanical.

It means something deep inside the breast.

Very often an invasive cirrhosa carcinoma or severe inflammation is grabbing onto the ducts and physically tethering pulling the nipple inward.

Acquired inversion is a major red flag for malignancy.

Okay, that's a perfect segue into section two of the chapter, clinical presentations and inflammatory disorders.

We've mapped the anatomy.

Now, how do these patients actually walk into the clinic?

What are their complaints?

Well, the landscape of discovery has completely changed over the last few decades.

In the old days, basically everyone presented with a palpable lump.

Now we have to divide presentations into screening versus symptomatic.

Screening meaning mammograms.

Right.

We are finding things long before they can be felt by a hand.

Mammograms primarily pick up two things,

abnormal densities or crucially calcifications.

We'll talk extensively about why breast cancer calcifies when we get to DCIS.

But let's say a patient does feel a lump in the shower.

The text draws out a statistic that I think should significantly lower the blood pressure of a lot of younger listeners.

It points out that for women under the age of 40, a new palpable breast mass is benign in more than 95 % of cases.

That is a massive relief.

95 % benign.

It's the fibroadenoma and simple cyst demographic.

But you have to watch the curve closely.

As age increases, that safety margin evaporates quickly.

By age 60 or 70, a newly discovered palpable mass is unfortunately much more likely to be malignant.

What about nipple discharge?

I feel like that symptom freaks patients out more than almost anything else.

It's visual, it ruins clothes, and it's highly alarming.

But the clinical rule of thumb is about the character of the fluid.

Is it milky, bilateral, and expressible, meaning you physically have to squeeze the breast to make it come out?

That's probably a hormonal issue like a prolactinoma or just benign changes.

But is the discharge spontaneous, unilateral, and bloody?

That's the major worry.

Because bloody means physical tissue damage inside.

Bloody means something structural is growing inside the ductal system and bleeding into the lumen.

It's actually most commonly a benign intraductal papilloma, but it can absolutely be a carcinoma.

You have to work it up surgically or with imaging to be sure.

Let's move to the things that actually hurt.

The inflammatory disorders.

The book lists a few of these, and some of them have incredibly specific clinical stories.

Acute mastitis seems pretty straightforward.

It is.

It's almost exclusively a disease of the postpartum breastfeeding period.

A mother is nursing, tiny fissures or cracks develop in the stressed skin of the nipple, and bacteria from the baby's mouth or the skin, usually Staphylococcus aureus, invade the tissue.

So it's a standard bacterial infection of the breast tissue?

Yes.

The breast gets hot, swollen, red, and extremely painful.

You treat it with appropriate antibiotics, but here is the key clinical pearl.

You must tell the mother to continue expressing milk from that breast.

If she stops because it hurts, the milk stagnates in the ducts and becomes a perfect bacterial culture medium.

The infection will just turn into a massive abscess.

But then there's a condition that looks exactly like a recurrent bacterial abscess, but it actually has nothing to do with breastfeeding.

The book calls it squamous metaplasia of lectiferous ducts or esmole.

Or recurrent seborrheolar abscess.

I actually love teaching this one, because the pathological mechanism is so clear and the underlying cause is so specific.

Robbins basically says point blank.

This is caused by smoking.

How does inhaling cigarette smoke cause an abscess in the breast?

That seems like a massive physiological leap.

It's all about a localized vitamin deficiency.

The normal lactiferous duct near the nipple is lined by that delicate double layer of cuboidal epithelial cells we talked about.

Maintaining that specialized lining requires vitamin A.

The toxins in tobacco smoke severely interfere with vitamin A metabolism locally in the breast tissue.

So the cells in the duct get confused because they lack the vitamin.

Exactly.

They undergo metaplasia.

To survive the toxic stress, they switch from being delicate, secretory duct cells to being tough, resilient squamous cells basically.

They turn into skin.

But here's the critical architectural problem.

Skin sheds dead keratin cells continuously.

Normal breast ducts don't.

So now you have a layer of skin going inside a narrow tube.

The tube radically gets completely plugged with dead keratin debris.

And the book specifically points this out in Figure 23 .3, right?

The keratin plug.

Right.

You can see the duct is massively dilated and blocked by this dense keratin plug.

Eventually the pressure builds up so much that the duct literally ruptures.

All that keratin spills out into the surrounding breast stroma.

The body's immune system hates free -flooding keratin.

It treats it like a foreign body and acts it fiercely.

You get massive granulomatous inflammation and a painful subariolar abscess.

So the surgeon goes in, grains the pus, gives antibiotics, but the squamous metaplasia is still lining the duct.

Precisely.

So the plug forms again.

And it ruptures again.

It's a vicious cycle.

The only curative treatment is to surgically excise the entire involved duct tract.

And obviously the patient has to stop smoking or it will just happen in another duct.

Fascinating.

Next is duct ectasia.

This sounds like an anatomical plumbing issue.

It's basically a disease of tissue aging.

It typically happens in older, multiparous women, usually in their 50s or 60s.

The large, lactiferous ducts near the nipple lose their elasticity and get abnormally dilated or ectatic.

They fill up with these thick,

inspecated secretions.

Inspecated?

That is such a classic pathology word.

It just means thickened, dehydrated, or sludge -like.

The book describes the fluid as

lipid -laden macrophages immune cells eating the stagnant fat.

The real problem arises when these dilated ducts leak this irritating sludge into the stroma.

It creates a chronic inflammatory response that eventually leads to dense fibrosis, or scarring.

And scarring feels hard on a physical exam.

It feels like a rock.

It creates an irregular, hard, fixed mass that can even retract the nipple due to the fibrotic tethering.

If you put your hand on it in the clinic, it feels like an invasive serous carcinoma.

That's why duct ectasia is known as the great imposter.

You almost always have to do a core needle biopsy just to prove to yourself and the patient that it's not malignant.

Speaking of imposters, the next one is fat necrosis.

This is the one that involves blunt trauma.

The classic board question scenario is the seatbelt injury from a car accident or maybe a patient walked hard into a door frame.

Blunt trauma physically ruptures and kills the fragile fat cells in the breast.

When fat cells die, they release their internal triglycerides, which get broken down into free fatty acids.

This triggers a very specific chemical reaction called saponification, basically making soap, which then leads to dystrophic calcification.

So the traumatized fat literally turns into chalk?

In a way, yes.

It forms a hard, localized calcified lump.

On a screening mammogram, it shows up as clustered calcifications, which is highly suspicious for cancer.

On physical exam, it feels like a hard, fixed cancer.

Even under the microscope at low power, the architecture looks chaotic and terrifying.

But when you zoom in on high power, you see the Hallmark ghost cells, the faint dead outlines of the ruptured fat cells surrounded by foamy macrophages and multi -nucleated giant cells trying to clean up the mess.

It is completely benign, but it guarantees a biopsy because it mimics cancer perfectly.

It's really amazing how many benign things present as incredibly scary things in the breast.

That's the overarching theme of breast pathology, really.

Most clinical findings aren't cancer, but our imaging and our hands can't always tell the difference, so we rely on the microscope to prove it.

Just to round out the inflammatory section, the text briefly mentions two rarer conditions,

lymphocytic mastopathy and granulomatous mastitis.

Lymphocytic mastopathy, or diabetic mastopathy, is fascinating.

It presents as single or multiple hard palpable masses, typically in women with long -standing type 1 diabetes or autoimmune thyroid disease.

Under the microscope, you see dense collagenized trauma surrounding atrophic ducts heavily infiltrated by lymphocytes.

It's thought to be an autoimmune reaction to matrix proteins that get glycosylated by the high blood sugar.

And the granulomatous mastitis is this rare idiopathic condition where you form non -necrotizing granulomas specifically centered on the breast lobules.

The key there for a pathologist is you must extensively stain for tuberculosis and fungi to rule out an infectious cause before calling it idiopathic.

Okay, let's organize these benign lumps.

Robbins uses a very specific structured system in section 3 of the chapter called benign epithelial proliferations.

It's essentially a risk ladder.

This classification is critical for patient counseling.

A woman gets a biopsy for a hemogram abnormality.

The report says it's benign.

But the clinician needs to know, how benign is it?

Is it ignore it and go home benign?

Or is it we need to watch you very closely with MRIs benign?

We group these lesions into three distinct buckets based on their subsequent risk of developing invasive cancer.

Let's start with bucket one, non -proliferative breast changes.

Historically, clinicians call this fibrocystic change.

This is the background noise of the

The book shows figure 23 .5 for this, highlighting the blue dome cysts.

Yes.

When a surgeon actually opens a breast with this condition, the cysts are filled with this turbid, semi -translucent fluid that literally looks blue through the cyst wall.

If you look at figure 23 .5, you'll see these cysts are often lined by apocrine metaplasia.

The normal cells transform to look like large pink apocrine sweat gland cells.

You also see fibrosis and adenosis, which just means an increase in the absolute number of Ashini per lobule without any weird cellular changes.

And the risk profile for this first bucket?

Zero.

The relative risk is 1 .00.

Having intensely lumpy, bumpy fibrocystic breasts is uncomfortable, but it does not increase your statistical risk of eventually getting breast cancer over the general population.

Okay, stepping up the ladder to bucket two, proliferative breast disease without atypia.

Now the risk ticks up slightly, about 1 .5 to 2 times the average risk.

This category means the epithelial cells are actively growing and multiplying.

That's the proliferative part, but they still look cytologically normal.

There's no atypia.

The blueprints are normal.

They're just building too many houses.

The main player the book focuses on here is usual ductal hyperplasia or UDH.

Remember, a normal breast duct has just two layers, liminal and myoepithelial.

In UDH, the luminal cells multiply inappropriately and pile up on top of each other.

They can completely fill and distend the duct.

But the key to diagnosing UDH under the microscope is the architectural pattern.

The book refers to the cells as streaming.

Streaming, like water.

Exactly.

The cells are swirling around each other.

They're oriented in parallel, flowing patterns.

And crucially, because the cells are somewhat randomly piled up, the empty spaces left between them are irregular, slit -like fenestrations.

They look like squash tear drops at the periphery of Let's look at figure 23 .6.

It shows this perfectly.

Why does the exact shape of the hole matter so much to a pathologist?

Because it's the main way we tell it apart from early cancer.

In low -grade ductal carcinoma in situ, or DCIS, the malignant cells are rigid, uniform, and monotonous.

They don't swirl or stream.

They form rigid geometric bridges and punch out perfect, round cookie -cutter holes.

If the holes are irregular, stretched, and slit -like, it's usually If they are perfectly round, like Swiss cheese, you start worrying about cancer.

That's a fantastic visual heuristic.

Slits equal good.

Perfect circles equal bad.

What else lives in the second bucket?

Sclerosing adenosus is a big one.

This is where you have way too many atini proliferating the adenosus.

But they are simultaneously getting squeezed and distorted by dense, ferbrotic scar tissue, the sclerosis.

It crushes the glands into thin cords, making it incredibly invasive and scary on a slide.

And it can form firm masses with calcifications.

But it is benign.

We also put intranuctal papillomas in this bucket, which are those fibrovascular tree -like growths inside the ducts that cause the bloody nipple discharge.

There's also a section here on gynecomastia, the male breast.

Right.

Gynecomastia belongs in this proliferative, without atypia bucket.

It's driven by an imbalance where estrogen levels overpower androgen levels.

You see it with liver cirrhosis, whether the liver can't clear estrogen, or with certain drugs, or in Kleinfelder syndrome.

Looking at Figure 23 .10, the histology of gynecomastia, it looks different than female breast tissue.

The key diagnostic feature of the male breast, even when stimulated by estrogen and gynecomastia, is that men generally do not form lobules.

You will see a massive proliferation of dense stroma and elongated branching ducts piling up with hyperplasia, but you won't see those terminal just the vines.

Moving to the top of the risk ladder, Bucket 3, proliferative breast disease with atypia.

Now we are in the real clinical danger zone.

The relative risk here jumps to 4 to 5 times higher than the general population.

This bucket includes atypical ductal hyperplasia, or ADH, and atypical lobular hyperplasia, ALH.

What does atypical actually mean in this specific context?

Are they cancer cells?

It means the cells have acquired the exact cytological and architectural features of carcinoma in situ.

They are monotonous, they look completely identical to each other, and in ADH they start forming those rigid, round cookie -cutter spaces.

Look at Figure 23 .11, it looks remarkably organized, which is bad.

So if it looks exactly like cancer, why isn't it diagnosed as cancer?

Because in pathology, sometimes it's a game of inches.

ADH looks morphologically identical to low -grade DCIS, but it's just too small.

The strict diagnostic criteria say that to call it the identical cells must completely involve at least two entire duct spaces, or span more than 2 millimeters in aggregate size.

If it's smaller than that, or only partially fills a duct, it's ADH.

It's a purely quantitative distinction.

So if you leave ADH alone and it grows half a millimeter bigger, it magically becomes DCIS.

Biologically and morphologically, yes, it's a continuum.

But here is the absolutely critical clinical implication that Robyn stresses.

If a woman has a biopsy and ADH or ALH is diagnosed in her left breast, her statistical risk of developing invasive cancer goes up significantly in both breasts, not just the left one.

Wait, really?

Why the opposite side?

The atypical cells aren't over there.

Because ADH and ALH aren't just direct precursors that turn into cancer right in that one spot.

They are essentially biological warning sirens.

They are markers of widespread genomic and hormonal instability in that patient's specific environment.

It tells the oncologist that the soil is bad everywhere.

So the whole field, both breasts, is at a highly elevated risk.

Wow.

Okay, that brings us right to the edge of the cliff.

Section four, carcinoma in situ,

the pre -invasive stage.

Right.

In situ literally translates to in place.

The cells are fully malignant.

They have the genetic mutations of cancer.

They look ugly and clone -like.

But, and here's our golden thread the whole chapter.

The myoepithelial bouncers are still holding the line.

The basement membrane is completely intact.

The cells are trapped inside the duct or the lobule.

They cannot metastasize.

Let's start with ductal carcinoma in situ, DCIS.

You mentioned earlier we find this mostly on mammograms.

We diagnose massive amounts of DCIS today, almost entirely because of screening mammography.

And that's because DCIS absolutely loves to calcify.

Walk me through the mechanism of that.

Why calcium?

As the malignant tumor cells rapidly multiply and completely fill up the center of the duct lumen, the cells right in the dead center get pushed further and further away from the vital blood vessels that surround the outside of the duct.

Eventually the diffusion limit of oxygen is reached.

The cells in the middle literally starve to death and undergo necrosis.

Dead necrotic tissue in the body rapidly attracts calcium deposits.

So the bright white talsifications the radiologist sees on the mammogram are actually the tombstones of starved cancer cells inside the duct.

That is a dark metaphor but perfectly accurate.

Pathologists subclassify DCIS based on its architectural pattern.

The nastiest, most aggressive one is Comito DCIS.

Comito like a blackhead on the skin.

Exactly like that.

If a surgeon cuts across a breast with Comito DCIS and gently squeezes the tissue, necrotic, cheesy material literally oozes out of the cut ducts like toothpaste from a tube.

Under the microscope, it's high grade.

The cells are wildly pleomorphic, meaning they have very ugly variable shapes and huge nuclei.

And there is a massive central zone of pink, dead Comito necrosis.

It calcifies heavily.

Versus the gentler architectural types.

Right.

Non -Comito DCIS.

You have cribriform DCIS, which makes those perfect rigid cookie cutter round spaces we talked about.

And you have micropapillary DCIS, which forms these little bulbous complex finger -like projections into the limb.

But notably they completely lack a central fibrovascular core, unlike a benign papilloma.

These non -Comito types are usually low grade.

Figure 23 .22 has great comparison shots of all these.

There is a very special clinically obvious manifestation of DCIS mentioned next called Paget disease of the nipple.

I think this one confuses a lot of students because it presents exactly like a dermatological skin rash.

It does.

The patient presents to the clinic complaining of a crusty, scaly, reddened, oozing nipple and looks exactly like severe eczema.

But they've tried topical steroid creams for a month and it hasn't improved at all.

What is actually happening biologically there?

The malignant DCIS cells that are sitting deep down in the major lactiferous ducts have learned a terrifying new trick.

Intrapithelial migration.

They literally crawl up the inside of the ductal system, breach the surface at the nipple, and spread out horizontally into the epidermis, the skin of the nipple, and the areola.

But to be clear, those aren't skin cancer cells like melanoma or squamous cell carcinomas.

There are malignant breast calendular cells living as unwanted guests in the skin.

Because they are bulky and foreign, they physically disrupt the tight waterproof seal of the normal skin cells.

This allows extracellular fluid to seep out onto the surface, which dries and causes that classic oozing crusty presentation.

The absolutely vital clinical takeaway here is, if you diagnose Paget disease on the nipple, you must assume there is an underlying hidden carcinoma, usually high -grade DCIS, or even invasive cancer, deeper inside that breast.

It is never just a skin disease.

Got it.

Now let's flip over to the other side of the in situ coin, lobular carcinoma in situ, or LCIS.

Reading this section, it seems to operate by a completely different set of biological rules than DCIS.

It really does.

To understand LCIS, and later invasive lobular carcinoma, you have to understand the function of one specific protein,

ecadherin.

The glue protein.

Exactly.

Ecadherin is the crucial transmembrane adhesion protein that essentially zips neighboring epithelial cells tightly together.

It allows them to stick and form organized sheets or perfect tubes.

In lobular carcinoma, the gene that codes for ecadherin, which is CDH1, is mutated or lost entirely.

No ecadherin equals no cellular glue.

So the cells just fall apart from each other.

We call it being discohesive.

Instead of forming nice tight geometric glands or organized streaming patterns, the malignant cells are totally disconnected.

They're small, round, and solitary.

In LCIS, they proliferate and fill up the entire lobule, but because they don't stick together, they don't distort the underlying architecture, they just pack it full.

Like filling a balloon with loose marbles.

You can see this perfectly in figure 23 .14.

And because they don't rapidly outgrow their and die like high -grade DCIS.

Right.

They rarely undergo necrosis, which means they rarely calcify.

And because they don't provoke a scar response, they don't form a hard mass.

So how do you ever find it?

It is practically invisible on mammography and physical exam.

LCIS is almost exclusively an incidental finding.

A surgeon does a biopsy for some unrelated calcification or a benign fibrodinoma.

The pathologist looks at the slide and says, oh, by the way, there's LCIS hiding in the background loggules here too.

And what does an incidental LCIS diagnosis actually mean for the patient's future?

It is a massive risk factor.

It carries an extremely high risk of subsequent invasive cancer.

But interestingly, having LCIS doesn't just mean you are destined to get invasive lobular cancer.

It increases the risk for invasive ductal carcinoma just as much.

Just like atypical hyperplasia, LCIS is a powerful marker of a generalized bilateral field defect in the risk for any type of invasive cancer.

Okay.

We've been hovering right at the edge of the cliff for a while.

Now let's finally jump off.

Section 5.

Invasive carcinoma.

The bouncers are dead.

The basement membrane is breached.

This is the main event.

Invasive carcinoma.

The tumor cells are now free to invade the stroma, enter the lymphatic channels, and travel to the liver, lungs, or bones.

But the most profound concept Robbins teaches in this epidemiology and pathogenesis section is that breast cancer is not a single monolithic disease.

It's actually a collection of distinct molecular diseases that travel down two very different evolutionary roads.

The text outlines this beautifully in figure 23 .1 summon as the two highways concept.

Breakdown Highway 1 for me.

Highway 1 is the low -grade pathway.

This accounts for the vast majority of all breast cancers, specifically the luminal subtypes.

What is driving the car on this highway?

Estrogen.

These tumors are highly ER positive, meaning they express the estrogen receptor and rely on the hormone to grow.

They tend to grow relatively slowly.

And what do the underlying genetics look like?

The signature, initiating mutations, are usually in a gene called PIK3CA.

And structurally, they have a very specific chromosomal signature.

They almost always lose the long arm of chromosome 16, known as 16q loss, and gain an extra copy of the long arm of chromosome 1.

So the progression down this highway is slow and linear.

Very linear.

It's a classic stepwise accumulation of hits over many years.

It starts as flat epithelial atypia, evolves into atypical ductal hyperplasia, progresses to low -grade DCIS, and finally breaches the membrane to become low -grade invasive luminal carcinoma.

Now contrast that entirely with Highway 2, the high -grade pathway.

Highway 2 is a high -speed catastrophic crash.

These tumors are generally not driven by estrogen.

They are driven by massive genomic instability.

The text brings up the classic guardian of the genome here.

TP53.

Mutations in the P53 tumor suppressor gene are the absolute hallmark of this high -grade pathway.

P53 is supposed to pause the cell cycle and fix DNA errors.

Without it, the genome essentially shatters.

You get massive chaotic chromosomal amplifications and deletions.

You also frequently see the amplification of the HER2 gene on this pathway.

And the progression timeline.

We simply don't see this slow 10 -year buildup through atypical hyperplasia.

These cancers seem to explode out of nowhere, presenting rapidly as highly necrotic high -grade comido DCIS and very quickly becoming aggressive invasive HER2 positive or triple negative carcinomas.

Before we lock into the specific molecular subtypes, we have to talk about the famous inherited genes BRCA1 and BRCA2.

It's important context.

Only about 5 to 10 percent of all breast cancers are driven by these specific highly penetrant single gene germline mutations.

But studying them has taught us so much about the biology of sporadic cancers.

What is the normal day -to -day job of a BRCA protein in a healthy cell?

DNA repair.

Specifically, a complex process called homologous recombination.

Our DNA suffers double -strand breaks all the time from background radiation or just copying errors.

If your DNA snaps in half, the BRCA complex uses the sister chromatid as a perfect template to flip the broken ends back together flawlessly without losing a single letter of code.

So if a patient inherits a mutated, broken BRCA1 gene, their cells simply can't fix those double -strand DNA breaks efficiently.

They have to rely on messy, error -prone backup repair systems.

Errors and mutations pile up rapidly.

Eventually, a breast or ovarian epithelial cell hits a critical mass of chaotic errors and transforms into cancer.

There is a really important clinical and pathological distinction between BRCA1 and BRCA2, though.

They don't cause the exact same types of tumors.

No, they don't.

BRCA1, which is located on chromosome 17, is heavily associated with triple -negative breast cancers, as well as a massive risk for ovarian carcinoma.

BRCA2, located on chromosome 13, is actually associated much more often with ER -positive breast cancers.

And crucially, for anyone taking a board exam, BRCA2 is the major known genetic driver of male breast cancer.

The text mentions a pharmacological here called synthetic lethality with PRP inhibitors.

Can you explain that mechanism?

Because the way the book describes it, it sounds like absolute sci -fi.

It is one of the most brilliant, elegant concepts in modern oncology.

Let's say a cancer cell has a mutated BRCA gene.

It has lost its primary, perfect DNA repair tool.

But it is still surviving and growing because it relies on a secondary backup repair tool called a PRP enzyme to hastily patch its DNA together enough to divide.

If we give the patient a drug that specifically blocks that PRP enzyme, it would take away their only remaining backup tool.

Exactly.

The cancer cell now has absolutely zero ways to fix its naturally occurring DNA breaks.

Its genome shreds itself, and the cancer cell dies via apoptosis.

But the beauty is the patient's normal, healthy cells, which still have one good, functional copy of the BRCA gene,

survive the drug perfectly fine because they don't need PRP.

They just use their working BRCA.

It is literally using the cancer's own specific genetic weakness against it to destroy it.

That is just phenomenal science.

Okay, moving into section six, molecular classification.

We've touched on this throughout, but let's formalize the major clinical buckets because this is how oncologists and pathologists actually talk about breast cancer today.

Right.

We don't just use microscopes anymore.

Every single invasive breast cancer gets tested for three vital biomarkers, ER for estrogen receptor, PR for progesterone receptor, and HER2, which is a growth factor receptor.

The combination of these results puts the tumor into one of four major molecular subtypes.

Bucket one is luminal A.

ER positive, HER2 negative, and crucially, they have a low proliferation rate, meaning a low CHI 67 index on staining.

This corresponds exactly to that low -grade Highway 1 we discussed.

It usually happens in older post -menopausal women.

While no cancer is good, this is the best breast cancer to have.

It grows slowly, rarely metastasizes early, and it responds beautifully to anti -estrogen hormonal therapies like tamoxifen or aromatase inhibitors.

Bucket two is luminal B.

These are also ER positive, but they're biologically meaner.

They have a much higher grade under the microscope and a high proliferation rate.

Sometimes they're also ATR2 positive.

These are the tricky borderline cancers.

They definitely need the hormonal therapy because they have estrogen receptors, but because they grow so fast, they often require harsh systemic chemotherapy as well.

Bucket three is HER2 positive.

These tumors have amplified the HR2 gene, creating millions of extra HR2 growth factor receptors on their cell surface.

They are constantly receiving signals to divide and conquer.

Historically, before the late 90s, these were considered some of the absolute worst, right?

Yes.

30 years ago, a HER2 positive diagnosis was devastating.

It was highly aggressive, it metastasized to the brain and visceral organs very early, and mortality was terrible.

But then science gave us Trastuzumab, also known as Herceptin.

The monoclonal antibody.

It's basically a guided missile.

It specifically locks onto the extracellular domain of the ATR2 protein on the cancer cell surface and physically shuts down the growth signaling.

It also flags the cancer cell for the immune system to destroy.

That single drug turned one of the highest mortality breast cancers into one of the most reliably treatable forms.

And finally, bucket four, triple negative.

Also known in the literature as basal -like.

These tumors are ER negative, PR negative, and HER2 negative.

And why is this specific bucket still so feared in the clinic?

Because we have no guided missiles for it.

We can't use tamoxifen to block estrogen because the tumor doesn't care about estrogen.

We can't use Herceptin because there's no HER2 target.

Because there are no specific receptors to target, we are largely forced to rely on traditional dumb cytotoxic chemotherapy,

basically just broadly poisoning all fast -growing cells in the body and hoping the cancer dies before the patient does.

And epidemiologically, it disproportionately affects certain specific groups.

Yes, significantly.

Triple negative breast cancer is far more common in young premenopausal women.

In African American women, and as we noted in women who carry a BRCA1 germline mutation, it is highly aggressive.

It has a high histological grade and it tends to relapse quickly, if not completely eradicated.

Okay, we know the underlying genetics and receptors.

Now let's get back to the microscope.

Section seven, morphology of invasive carcinoma.

What do these tumors actually look like to a pathologist?

Well, the vast majority of them, about 75%, fall into a category we now call invasive carcinoma of no special type, or NST.

The older textbooks used to call this invasive ductual carcinoma, right?

Why the name change?

Because the old name implied they arose exclusively from the ducts, while lobular carcinomas arose from the lobules.

We now know that's not true.

Both actually arise from the TVLU.

So unless it has a very specific, weird microscopic pattern like lobular or mucinous, it gets dumped into the generic NST bucket.

And the classic gross description for an NST tumor in the pathology lab is cirrus.

Cirrus means hard,

rock hard.

If a pathologist takes a scalpel and cuts through one of these tumors fresh from the OR, it physically feels like cutting through an ripe pear or raw water chestnut.

It literally makes a grating sound against the blade.

Why is it so hard?

Are the cancer cells themselves physically dense?

No, the cancer cells are soft.

The hardness comes from desmoplasia.

As the invasive cancer cells tear through the basement membrane and invade the normal breast fat, the host tissue freaks out.

It reacts to the invasion by seriously laying down massive amounts of dense, disorganized collagen and fibrotic scar tissue.

It's essentially the body vainly attempting to concrete over the tumor to wall it off.

That dense, rock hard stroma is what the woman feels as a lump and what the pathologist feels against the knife.

Look at the growth image in figure 23 .20.

You can see that dense, white, stellate star -shaped scar pulling on the surrounding yellow fat.

And once we have it under the microscope, we have to grade it using the Nottingham score.

This is a strictly standardized grading system to tell the oncologist how aggressive the NST tumor looks.

It's a simple three -point system adding up to a total score.

First, tubules.

Is the tumor still trying to form organized glands or tubes?

Tumors that form lots of tubules get a lower, better score.

Second,

nuclear pleomorphism.

Do the nuclei look relatively normal and uniform, or are they massive, dark, and crazy -looking?

Crazier nuclei get a higher, worse score.

And third, mitotic count.

How many cells are actively caught in the middle of dividing?

More division means a higher grade.

Figure 23 .21 shows a beautiful comparison between a well differentiated grade 1 tumor making nice tubules and a poorly differentiated grade 3 tumor just growing in ugly solid sheets.

Now, how does all of that compare to the second most common type?

Invasive lobular carcinoma.

Lobular carcinoma goes completely back to that ECAT here in law signature we discussed with LCIS.

Because these invasive cells have absolutely no cellular glue, they are incapable of forming tubules or solid sheets.

How do they grow?

They infiltrate through the stroma in single file lines.

Indian filing.

That's the classic pathological term.

It's just chains of solitary cells silently marching one by one through the dense collagen fibers.

Look at figure 23 .22a.

It's a perfect example.

And because they don't clump up into massive aggressive nests, they often do not trigger that massive desmoplastic fibrotic reaction that NST tumors do.

So they aren't rock hard?

Very often they aren't.

They can feel just like an area of slightly thick and normal breast tissue.

They are incredibly stealthy.

They are hard to feel on exam.

And they are notoriously difficult to see on mammograms because they don't form a dense mass.

The book also highlights that their metastasis pattern is completely bizarre compared to typical breast cancer.

It is the stuff of nightmares for oncologists.

Normal NST ductal cancers predictably metastasize to the lungs, the liver, and the bones.

Lobular carcinoma, likely because of its single celled discohesive nature, loves to spread to weird, diffuse places.

It coats the peritoneum, lining of the belly.

It infiltrates the gastrointestinal tract lining.

It spreads to the ovaries, causing what's known as a Kruckenberg tumor.

It even spreads to the leptomenages, the thin coating of the brain, and spinal cord.

That is a profoundly important clinical distinction.

So if you have a patient with a known history of lobular breast cancer, and five years later she comes into the clinic complaining of vague stomach pain or bowel issues, you don't just write it off as IBS.

Absolutely not.

You have to aggressively work her up for metastasis from her breast cancer.

Okay, there are a few other special histologic types of invasive cancer briefly mentioned.

Let's do a quick hit on these.

Sure.

Mucinous or colloid carcinoma is bizarre.

Grossly, it looks and feels like soft, pale gray jelly.

Under the microscope, the tumor cells literally sit floating in massive lakes of extracellular mucin that they've secreted.

It looks totally disgusting, but it actually has a surprisingly excellent prognosis.

Then there's tubular carcinoma, which consists exclusively of extremely well -formed, perfect little tubules.

It is almost always grade one, and has a fantastic prognosis, rarely metastasizing.

And medullary carcinoma.

Medullary is interesting because it's usually a specific morphological presentation of a triple negative BRCA1 -associated cancer.

Instead of being hard and serous, it forms soft, fleshy masses with pushing, rounded borders.

Under the microscope, you see solid syncytial sheets of huge, ugly pleomorphic cells.

But they are completely heavily infiltrated by lymphocytes, the patient's own T cells attacking the tumor.

Despite looking incredibly high -grade cytologically, the intense immune response actually gives it a slightly better prognosis than standard triple negative cancers.

And finally, the most terrifying one, inflammatory carcinoma.

We mentioned this earlier when talking about mastitis.

Right.

This is strictly a clinical diagnosis backed up by pathology.

It is the most aggressive and rapidly fatal form of breast cancer.

The patient presents with a breast that is swollen,

heavily erythematous red hot, and tender.

The skin itself looks exactly like the dimpled surface of an orange peel.

The classic peau d 'or orange sign.

Why does the skin dimple like that?

It's not actually inflammation in the traditional immune sense.

The redness and swelling happen because highly aggressive tumor cells have invaded and completely physically blocked the dermal lymphatic channels in the skin.

So the limb fluid can't drain away.

Exactly.

The breast skin becomes massively engorged with backed up limb fluid.

It puffs up immensely, but the skin is tightly tethered down at the tiny hair follicles by ligaments.

So the skin swells up around the follicles, creating those deep dimples, just like an orange peel.

And the grim reality for the pathologist and oncologist is that because the tumor is already massively filling the lymphatic vessels of the skin, it has by definition already spread systemically.

It is automatically classified as a very advanced stage T4 cancer the moment you see it.

The prognosis is very poor.

That is incredibly heavy stuff.

Okay, let's take a breath and finish out the chapter with section eight.

Something slightly less malignant.

Stromal tumors.

We've spent this entire time talking about the epithelial cells, the functional grapes and vines.

What about tumors of the dirt they grow in?

The stroma.

Robbins divides these neatly into two categories.

Intralobular stroma, which is the spiralized, hormonally responsive, loose dirt immediately surrounding the achini inside the TDLU.

And intralobular stroma, which is just a dense, structural, generic connective tissue filling the rest of the breast.

Tumors of that specialized intralobular stroma give us the fibrodinoma.

Right.

This is the absolute most common benign breast tumor, especially in young women in their 20s and 30s.

Clinically, it's famous for being called the breast mouse.

Because it scurries around?

Because it is perfectly circumscribed, spherical and rubbery.

When a doctor tries to palpate it during an exam, it literally slips and slides away from under their fingers.

It is highly mobile within the breast tissue.

What drives it genetically?

The book points out that many of these have specific driver mutations in the ME12 gene.

Under the microscope, look at figure 23 .24.

It's a biphasic tumor.

You see a massive benign proliferation of the pale stroma, but you also see proliferation of the epithelial glands.

The stroma grows so rapidly and densely that it literally squishes the surrounding glandular ducts into tight, branching, slit -like spaces that look like deer antlers.

And because that specialized stroma is highly responsive to estrogen, fibrodinomas will often noticeably grow during pregnancy and then completely calcify and shrink away after menopause.

And then there's its much larger, angrier cousin, the philodes tumor.

Philodes translates from Greek to leaf -like.

These also arise from the intralobular stroma and often share that ME12 mutation, but they acquire additional mutations, like in the Tert promoter.

Grossly, these can grow to be massive, lobulated tumors taking up the whole breast.

Why leaf -like?

Because the stroma grows so aggressively that it putches up into the cystic spaces, covered by a layer of epithelium, creating these large, bulbous architectural protrusions that look like the broad leaves of a plant under the microscope.

Are they benign or malignant?

They span a spectrum.

Unlike a fibrodinoma, which is always benign, a philodes tumor can be classified as benign, borderline, or fully malignant.

How do you tell a difference?

As a pathologist, you completely ignore the epithelial cells that are just innocent bystanders being pushed around.

You stare strictly at the stromal cells.

How tightly packed are they?

How much atypia do their nuclei have?

And most importantly, how many mitotic figures dividing cells do you count per high -power field?

If the stroma is highly cellular, rapidly dividing, and has infiltrative borders pushing into the surrounding fat, it's a malignant philodes tumor, which is basically a sarcoma.

And speaking of sarcomas, there is one final tumor mentioned that arises from the generic interlobular stroma, the angiosarcoma.

This is a highly malignant aggressive cancer arising from the endothelial cells that line the blood vessels within the breast stroma.

They can arise randomly, sporadically in young women.

But there is a very specific, tragic clinical context that Robbins highlights called Stuart Tree's syndrome.

This is directly related to prior breast cancer treatment, right?

Yes.

In the past, when surgeons performed highly radical mastectomies, they would strip out all the axillary lymph nodes to ensure they got all the cancer.

That completely disrupted the lymphatic drainage of the patient's arm, leading to massive, chronic, lifelong swelling of the arm, known as lymphedema.

Decades later, that chronic, severe swelling and localized immune dysfunction can actually trigger an angiosarcoma to arise in the skin and soft tissue of that chronically swollen arm.

Wow.

It's a profound reminder that every single medical intervention we do has long -term consequences.

It absolutely does.

Well, okay.

We have successfully traversed the entirety of Chapter 23.

From the basic great cluster anatomy of the TDLU, through the vital concept of the myoepithelial bouncers, the crazy vitamin A deficiency of smoking causing smold, the e -cadherin loss that makes lobular cancer so stealthy, all the way to the molecular highways and targeted therapies of invasive carcinoma.

It is an incredibly dense, fact -heavy chapter.

But my hope is that by talking through it this way, if you keep the underlying mechanisms in mind, why the coming of necrosis leads to calcification, why the e -cadherin loss changes the cell shape, why the BRCA mutation makes PLP inhibitors work, it becomes a logical flowing story that you can derive on a test, rather than just a massive list of disconnected facts you have to brute force memorize.

For everyone listening out there, whether you are currently driving to the hospital for your surgery rotation, sitting in the library trying to cram, or just trying to stay awake on a long night shift, we really hope this format helps you connect those dots.

As a final thought, mull this over.

We spent so much time talking about the malignant epithelial cells,

but notice how much the stroma dictated the disease.

The desmaplasia making the lump hard, the stroma driving the phylloids tumor.

The future of breast pathology might just be finding ways to treat the dirt, rather than just attacking the seed.

Pathology is always the why of medicine.

Never forget that when you are treating the patient in front of you.

Good luck on the exam.

This has been a last -minute lecture from the Deep Dive team.

Thank you so much for listening.

Signing off.